Amgen Inc. $AMGN Shares Purchased by Mariner LLC

Mariner LLC lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 1.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,053,171 shares of the medical research company’s stock after acquiring an additional 16,031 shares during the period. Mariner LLC owned 0.20% of Amgen worth $297,162,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in AMGN. West Family Investments Inc. raised its holdings in Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after purchasing an additional 30 shares in the last quarter. Viawealth LLC boosted its stake in Amgen by 0.4% during the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after purchasing an additional 30 shares in the last quarter. LOM Asset Management Ltd increased its position in shares of Amgen by 1.2% during the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after purchasing an additional 30 shares during the period. TAGStone Capital Inc. increased its position in shares of Amgen by 0.8% during the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after purchasing an additional 32 shares during the period. Finally, BBR Partners LLC raised its stake in shares of Amgen by 0.5% in the 3rd quarter. BBR Partners LLC now owns 7,117 shares of the medical research company’s stock worth $2,008,000 after buying an additional 32 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Royal Bank Of Canada upped their price objective on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. HSBC reaffirmed a “buy” rating and set a $425.00 target price on shares of Amgen in a report on Wednesday, December 10th. Jefferies Financial Group assumed coverage on shares of Amgen in a report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price target for the company. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Finally, Citigroup lifted their price objective on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Amgen currently has an average rating of “Hold” and a consensus target price of $354.00.

Amgen Trading Up 0.0%

Shares of NASDAQ:AMGN opened at $366.25 on Tuesday. The firm has a fifty day moving average of $358.64 and a two-hundred day moving average of $326.25. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The firm has a market capitalization of $197.43 billion, a P/E ratio of 25.74, a price-to-earnings-growth ratio of 3.63 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the prior year, the business posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.8%. Amgen’s dividend payout ratio (DPR) is 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.